Cargando…

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination

BACKGROUND: BBIBP-CorV and CoronaVac inactivated COVID-19 vaccines are widely-used, World Health Organization-emergency-listed vaccines. Understanding antibody level changes over time after vaccination is important for booster dose policies. We evaluated neutralizing antibody (nAb) titers and associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fuzhen, Huang, Baoying, Lv, Huakun, Feng, Lizhong, Ren, Weihong, Wang, Xiaoqi, Tang, Lin, Liu, Qianqian, Wu, Dan, Zheng, Hui, An, Zhijie, Deng, Yao, Zhao, Li, Ye, Fei, Wang, Wenling, Zhang, Hangjie, Chang, Shaoying, Liao, Yuting, Chen, Fengyang, Rodewald, Lance E., Gao, George F., Yin, Zundong, Tan, Wenjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501884/ https://www.ncbi.nlm.nih.gov/pubmed/36159863 http://dx.doi.org/10.3389/fimmu.2022.967051

Ejemplares similares

Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study
por: Wang, Xiaoqi, et al.
Publicado: (2022)

Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant
por: Wang, Fuzhen, et al.
Publicado: (2021)

Vaccination strategy and challenges for consolidating successful containment of covid-19 with population immunity in China
por: An, Zhijie, et al.
Publicado: (2021)

“If the world doesn’t share the vaccine, the virus will take on the world”
por: Yin, Zundong, et al.
Publicado: (2021)

Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
por: Wang, Yamin, et al.
Publicado: (2021)

Vaccinate with Confidence and Finish Strong
por: Rodewald, Lance, et al.
Publicado: (2022)

Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study
por: Tang, Lin, et al.
Publicado: (2022)

Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection
por: Wang, Fuzhen, et al.
Publicado: (2023)

Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants — China, May 21, 2021–February 28, 2022
por: Li, Mingshuang, et al.
Publicado: (2022)

Prioritization of Vaccines for Inclusion into China’s Expanded Program on Immunization: Evidence from Experts’ Knowledge and Opinions
por: Ma, Chao, et al.
Publicado: (2022)

Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
por: Xu, Shiyao, et al.
Publicado: (2023)

Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021
por: Ma, Chao, et al.
Publicado: (2022)

Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial
por: Li, Yan, et al.
Publicado: (2021)

Senior Research Scholars in China CDC’s National Immunization Program
por: Wang, Miao, et al.
Publicado: (2021)

Vaccination Guidelines During and After the COVID-19 Epidemic in China
por: Yu, Wenzhou, et al.
Publicado: (2020)

The National Immunization Advisory Committee in China: Roles of National Experts in Making Evidence-Based Recommendations for Immunization
por: Ma, Chao, et al.
Publicado: (2019)

Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus
por: Lan, Jiaming, et al.
Publicado: (2018)

Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study
por: Hua, Qianhui, et al.
Publicado: (2022)

Effectiveness of Inactivated COVID-19 Vaccines against Delta-Variant COVID-19: Evidence from an Outbreak in Inner Mongolia Autonomous Region, China
por: Ma, Chao, et al.
Publicado: (2023)

Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China
por: Shenyu, Wang, et al.
Publicado: (2022)

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
por: Wu, Dan, et al.
Publicado: (2022)

Effectiveness of Catch-Up Vaccinations after COVID-19 Containment — China, 2020
por: Wu, Jing, et al.
Publicado: (2020)

Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
por: Zhang, Hangjie, et al.
Publicado: (2023)

Immunogenicity of a trivalent influenza vaccine and persistence of induced immunity in adults aged ≥60 years in Taizhou City, Zhejiang Province, China, during the 2018–2019 season
por: Liao, Yuting, et al.
Publicado: (2022)

Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
por: Wang, Wenling, et al.
Publicado: (2019)

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults
por: Zhang, Hangjie, et al.
Publicado: (2023)

Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021
por: Yang, Hong, et al.
Publicado: (2023)

Exporting China’s Successes in Vaccine Preventable Hepatitis
por: Rodewald, Lance E.
Publicado: (2020)

Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
por: Zhang, Haiying, et al.
Publicado: (2022)

Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro
por: Yang, Ren, et al.
Publicado: (2020)

Effects of Three Major Immunization Interventions on Measles Control — China, 1952–2021
por: Song, Quanwei, et al.
Publicado: (2023)

Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study
por: Xu, Nani, et al.
Publicado: (2023)

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)
por: Liao, Yuting, et al.
Publicado: (2022)

Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine
por: Huang, Qingrui, et al.
Publicado: (2022)

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
por: Chen, Xinhua, et al.
Publicado: (2022)

Progress Towards Hepatitis A Control and Prevention Through 2019: the National Immunization Program of China
por: Sun, Xiaojin, et al.
Publicado: (2020)

Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
por: Zhang, Yuntao, et al.
Publicado: (2022)

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice
por: Zhao, Zhimin, et al.
Publicado: (2021)

Accelerating into Immunization Agenda 2030 with momentum from China’s successful COVID-19 vaccination campaign during dynamic COVID Zero
por: Rodewald, Lance E.
Publicado: (2023)

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3hc2ett4ispc0uf5074eofi0bb